Adjuvant therapy for resected non-small-cell lung cancer: Past, present, and future

被引：2
作者：
Juergens R.A. [1 ]
Brahmer J.R. [1 ]
机构：
[1] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-2410
来源：
Current Oncology Reports | 2005年 / 7卷 / 4期
关键词：
Vinorelbine; Vindesine; Japan Clinical Oncology Group; Lung Cancer Surgery; Lung Cancer Study Group;
D O I：
10.1007/s11912-005-0046-5
中图分类号：
学科分类号：
摘要：
Non-small-cell lung cancer has the highest mortality of all malignancies worldwide. Unfortunately, only the minority of patients diagnosed will have potentially curable disease. Over the past 30 years, dozens of trials have been conducted assessing adjuvant treatments to augment the survival advantage offered by surgery. It has only been in the past 5 years that promising results have begun to be seen. Cisplatin-based therapy has now been shown to provide an additional survival benefit in several trials and in a recent meta-analysis. The goal of this paper is to review the data on adjuvant therapies that have emerged over the past 30 years, focusing specifically on the trials that have been published in the past 5 years. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：248 / 254
页数：6
相关论文
共 34 条
  • [1] Jemal A., Murray T., Ward E., Et al., Cancer statistics, 2005, CA Cancer J. Clin., 55, pp. 10-30, (2005)
  • [2] Immerman S.C., Vanecko R.M., Fry W.A., Et al., Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure, Ann. Thorac. Surg., 32, pp. 23-27, (1981)
  • [3] Ginsberg R.J., Rubinstein L.V., Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer, Ann. Thorac. Surg., 60, pp. 615-622, (1995)
  • [4] Mountain C.F., The international system for staging lung cancer, Semin. Surg. Oncol., 18, pp. 106-115, (2000)
  • [5] Postoperative radiotherapy in non-small cell lung cancer: Systemic review and meta-analysis of individual patient data from nine randomised controlled trials, Lancet, 352, pp. 257-263, (1998)
  • [6] Arriagada R., Bergman B., Dunant A., Et al., Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer, N. Engl. J. Med., 350, pp. 351-360, (2004)
  • [7] Holmes E.C., Gail M., Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma, J. Clin. Oncol., 4, pp. 710-715, (1986)
  • [8] The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer, J. Clin. Oncol., 6, pp. 9-17, (1988)
  • [9] Feld R., Rubenstein L., Thomas P.A., Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer, J. Natl. Cancer Inst., 85, pp. 299-306, (1993)
  • [10] Niiranen A., Niitamo-Horhonen S., Kouri M., Et al., Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: A randomized study, J. Clin. Oncol., 10, pp. 1927-1932, (1992)
1234